Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.58 |
| ▸ | ACLY | P53396 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.44 |
| ▸ | TAS2R14 | Q9NYV8 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17453062 | 0.84 | APLNR (0.55) | APLNRACLYALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL11609 | 0.83 | APLNR (0.71) | APLNRACLYALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL17453055 | 0.80 | APLNR (0.62) | APLNRACLYALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL24461223 | 0.78 | APLNR (0.59) | APLNRACLYALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL18662141 | 0.78 | APLNR (0.59) | APLNRACLYALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL15094002 | 0.78 | APLNR (0.59) | APLNRACLYALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL27222358 | 0.75 | APLNR (0.77) | APLNRACLYALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL13193241 | 0.75 | APLNR (0.56) | APLNRACLYALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL18662058 | 0.75 | APLNR (0.56) | APLNRACLYALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL14285692 | 0.74 | TAS2R14 (0.64) | APLNRALDH1A1TAS2R14ACHEPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968356-B1 | S-IMINO-S-OXO IMINOTHIADIAZINE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME (US) | 2018-03-07 | — | — | EP | disclosed |
| US-9428476-B2 | S-imino-S-oxo-iminothiadiazine compounds as BACE inhibitors, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20160016923-A1 | S-IMINO-S-OXO-IMINOTHIADIAZINE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016923-A1 | S-IMINO-S-OXO-IMINOTHIADIAZINE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, BACE2, APP | APLNR 2974/4885ACLY 2962/4885ALDH1A1 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.